MAOA is associated with methylphenidate improvement of oppositional symptoms in boys with attention deficit hyperactivity disorder

International Journal of Neuropsychopharmacology

Volumn 12, Issue 5, 2009, Pages 709-714

  Guimares, Ana P ^a   Zeni, Cristian ^a   Polanczyk, Guilherme ^b   Genro, Julia P ^a   Roman, Tatiana ^a   Rohde, Luis A ^a   Hutz, Mara H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b DUKE UNIVERSITY   (United States)

Author keywords

ADHD; MAOA; Methylphenidate; Oppositional symptoms; Pharmacogenetic

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; METHYLPHENIDATE;

ALLELE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONDUCT DISORDER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPPOSITIONAL DEFIANT DISORDER; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHIATRIST; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; HUMANS; MALE; METHYLPHENIDATE; MONOAMINE OXIDASE; PSYCHIATRIC STATUS RATING SCALES;

EID: 69749102706     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709000212     Document Type: Article

References (27)

1. Arnsten AF, Li BM (2005). Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biological Psychiatry 57, 1377-1384.
2. Biederman J, Newcorn J, Sprich S (1991). Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. American Journal of Psychiatry 148, 564-577.
3. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, Taylor A, Poulton R (2002). Role of genotype in the cycle of violence in maltreated children. Science 297, 851-854.
4. Cohen J (1998). Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, New Jersey: Lawrence Erlbaum Associates.
5. Contini V, Marques FCZ, Garcia CED, Hutz MH, Baú CHD (2006). MAOA-uVNTR polymorphism in a Brazilian sample: further support for the association with impulsive behaviors and alcohol Dependence. American Journal of Medical Genetics 141B, 305-308.
6. Goldman LS, Genel M, Bezman RJ, Slanetz PJ (1998). Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Journal of the American Medical Association 279, 1100-1107.
7. Huang YY, Cate SP, Battistuzzi C, Oquendo MA, Brent D, Mann JJ (2004). An association between a functional polymorphism in the monoamine oxidase a gene promoter, impulsive traits and early abuse experiences. Neuropsychopharmacology 29, 1498-1505.
8. Kim-Cohen J, Caspi A, Taylor A, Williams B, Newcombe R, Craig IW, Moffitt TE (2006). MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Molecular Psychiatry 11, 903-913.
9. Kuczenski R, Segal DS (1997). Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. Journal of Neurochemistry 68, 2032-2037.
10. Levy F (1991). The dopamine theory of attention deficit hyperactivity disorder (ADHD). Australian and New Zealand Journal of Psychiatry 25, 277-283.
11. Manuck SB, Flory JD, Ferrell RE, Mann JJ, Muldoon MF (2000). A regulatory polymorphism of the monoamine oxidase-A gene may be associated with variability in aggression, impulsivity, and central nervous system serotonergic responsivity. Psychiatry Research 95, 9-23.
12. Mick E, Faraone SV (2008). Genetics of attention deficit hyperactivity disorder. Child and Adolescent Psychiatric Clinics North American 17, 261-284.
13. Mössner R, Simantov R, Marx A, Lesch KP, Seif I (2006). Aberrant accumulation of serotonin in dopaminergic neurons. Neuroscience Letters 401, 49-54.
14. MTA Cooperative Group (1999). Multimodal Treatment Study of Children With ADHD. A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. Archives of General Psychiatry 56, 1073-1086.
15. Newman TK, Syagailo YV, Barr CS, Wendland JR, Champoux M, Graessle M, Suomi SJ, Highley JD, Lesch KP (2005). Monoamine oxidase A gene promoter variation and rearing experience influences aggressive behavior in rhesus monkeys. Biological Psychiatry 57, 167-172.
16. Orvaschel H (1985). Psychiatric interviews suitable for use in research with children and adolescents. Psychopharmacology Bulletin 21, 737-745.
17. Passamonti L, Fera F, Magariello A, Cerasa A, Gioia MC, Muglia M, Nicoletti G, Gallo O, Provinciali L, Quattrone A (2006). Monoamine oxidase-a genetic variations influence brain activity associated with inhibitory control: new insight into the neural correlates of impulsivity. Biological Psychiatry 59, 334-340.
18. Polanczyk P, Silva de Lima M, Horta BL, Biederman J, Rohde LA (2007a). The worldwide prevalence of ADHD: a systematic review and metaregression analysis. American Journal of Psychiatry 164, 942-948.
19. Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH, Rohde LS (2007b). Association of the adrenergic a2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Archives of General Psychiatry 64, 218-224.
20. Rohde LA (2002). ADHD in Brazil: the DSM-IV criteria in a culturally different population. Journal of the American Academy of Child & Adolescent Psychiatry 41, 1131-1133.
21. Sabol SZ, Hu S, Hamer D (1998). A functional polymorphism in the monoamine oxidase A gene promoter. Human Genetics 103, 273-279.
22. Santosh PJ, Taylor E (2000). Stimulant drugs. European Child & Adolescent Psychiatry 9, 127-143.
23. Seeman P, Madras BK (1998). Anti-hyperactivity medication: methylphenidate and amphetamine. Molecular Psychiatry 3, 386-396.
24. Sinzig J, Döpfner M, Lehmkuhl G (2007). Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/ hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 17, 421-432.
25. Solanto MV (1998). Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behavioural Brain Research 94, 127-152.
26. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliot GR, Greenhill LL, et al. (2001). Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child & Adolescent Psychiatry 40, 168-1779.
27. Zeni CP, Guimarães AP, Polanczyk GV, Genro JP, Roman T, Hutz MH, Rohde LA (2007). No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/hyperactivity disorder. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics 144, 391-394.